Clinical trials
Lipid Metabolism Disorders trials in Germany
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
11 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2010 | 1 |
| 2014 | 2 |
| 2015 | 1 |
| 2017 | 2 |
| 2018 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 6 |
| Active, not recruiting | 1 |
| Recruiting | 1 |
| Terminated | 1 |
| Unknown status | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| 89bio, Inc. | 1 |
| Alexandra Miriam Kiess | 1 |
| Alexion Pharmaceuticals, Inc. | 1 |
| CENTOGENE GmbH Rostock | 1 |
| Charite University, Berlin, Germany | 1 |
| Eli Lilly and Company | 1 |
| German Diabetes Center | 1 |
| Ludwig-Maximilians - University of Munich | 1 |
| Shire | 1 |
| Sumitomo Pharma Switzerland GmbH | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Lipid Metabolism Disorders | 11 |
| Metabolic Diseases | 6 |
| Genetic Diseases, Inborn | 4 |
| Lysosomal Storage Diseases | 4 |
| Dyslipidemias | 3 |
| Lipidoses | 3 |
| Metabolism, Inborn Errors | 3 |
| Brain Diseases | 2 |
| Brain Diseases, Metabolic, Inborn | 2 |
| Central Nervous System Diseases | 2 |
Trials
Showing 26 to 11 of 11. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.